Next Article in Journal
In Vitro Cytotoxicity Evaluation of the Magnéli Phase Titanium Suboxides (TixO2x−1) on A549 Human Lung Cells
Previous Article in Journal
In Vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in Nicotiana benthamiana Plants
Article Menu
Issue 1 (January-1) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2019, 20(1), 195; https://doi.org/10.3390/ijms20010195

Zhile Capsule Exerts Antidepressant-Like Effects through Upregulation of the BDNF Signaling Pathway and Neuroprotection

1
Jiangsu Key Laboratory for Pharmacolgy and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
2
Zhejiang CN Strong Pharmaceutical Co., Ltd., Hangzhou 310000, China
3
State Key Laboratory Cultivation Base for Traditional Chinese Medicine (TCM) Quality and Efficacy, Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
4
Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing 210023, China
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 7 December 2018 / Revised: 29 December 2018 / Accepted: 31 December 2018 / Published: 8 January 2019
(This article belongs to the Section Molecular Neurobiology)
Full-Text   |   PDF [3285 KB, uploaded 8 January 2019]   |  
  |   Review Reports

Abstract

Major depressive disorder is now becoming a common disease in daily life, and most patients do not have satisfactory treatment outcomes. We herein evaluated the therapeutic effects of Zhile capsule and clarified the molecular mechanism. A rat model of chronic unpredictable mild stress-induced depression was established to assess the antidepressant-like effects of Zhile by using the sucrose preference test, open field test, forced swim test, tail suspension test and HPLC. Systems pharmacology was then performed to unravel the underlying mechanism which was confirmed by western blot, enzyme-linked immunosorbent assay, and qPCR. Zhile alleviated depression-like behaviors by upregulating the cAMP-CREB-BDNF (brain-derived neurotrophic factor) axis to exert neuroprotective effects. It may be beneficial to depressive patients in clinical practice. View Full-Text
Keywords: major depressive disorder; chronic unpredictable mild stress; systems pharmacology; brain-derived neurotrophic factor; neuroprotection major depressive disorder; chronic unpredictable mild stress; systems pharmacology; brain-derived neurotrophic factor; neuroprotection
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Wu, J.; Zhang, T.; Yu, L.; Huang, S.; Yang, Y.; Yu, S.; Li, J.; Cao, Y.; Wei, Z.; Li, X.; Wu, Y.; Chen, W.; Wang, A.; Lu, Y. Zhile Capsule Exerts Antidepressant-Like Effects through Upregulation of the BDNF Signaling Pathway and Neuroprotection. Int. J. Mol. Sci. 2019, 20, 195.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top